What is the recommended time to resume alendronate (bisphosphonate) therapy after a dental extraction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

It is recommended to wait at least 7-10 days after a dental extraction before resuming alendronate, as this allows for initial healing of the extraction site and formation of a blood clot, reducing the risk of osteonecrosis of the jaw (ONJ) 1. When considering the resumption of alendronate after a dental extraction, it's crucial to weigh the risks and benefits, particularly the risk of ONJ, which is a rare but serious condition. The studies provided indicate that the risk of ONJ is associated with the use of bisphosphonates like alendronate, especially after tooth extractions 2, 3.

Key Considerations

  • The risk of ONJ is increased with long-term use of alendronate and after tooth extractions 1, 2.
  • The overall incidence of bisphosphonate-related ONJ is low but significant, ranging from 0.7% to 12% 3.
  • Recent and long-term use of alendronate is associated with an increased risk of surgically treated ONJ 2.

Recommendations for Resuming Alendronate

  • Wait for at least 7-10 days after a dental extraction before resuming alendronate to allow for initial healing and reduce the risk of ONJ.
  • Follow standard administration guidelines when resuming alendronate: take it first thing in the morning with a full glass of water, remain upright, and avoid eating, drinking, or taking other medications for at least 30 minutes afterward.
  • Consult with both your dentist and the prescribing physician before resuming alendronate after dental work, as individual circumstances may require adjustments to this general guideline.

Additional Considerations

  • Teriparatide has been shown to be effective in the treatment of medication-related osteonecrosis of the jaw (MRONJ) and may be considered as an adjunctive treatment in some cases 4, 5.
  • The management of MRONJ is challenging, and standard treatment guidelines have yet to be established, highlighting the need for careful consideration and consultation with healthcare professionals 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.